|
|
Volumn 96, Issue 24, 2004, Pages 1807-1808
|
|
Rexinoids may be ready for prime time in prevention, but challenges remain
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID;
ALITRETINOIN;
ANTINEOPLASTIC AGENT;
ARZOXIFENE;
BEXAROTENE;
CASPASE 3;
CELECOXIB;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITOR;
ESTROGEN RECEPTOR;
RETINOID X RECEPTOR;
REXINOID DERIVATIVE;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
TRANSFORMING GROWTH FACTOR BETA3;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
BREAST CANCER;
CANCER CELL;
CANCER INHIBITION;
CANCER PREVENTION;
CANCER RESEARCH;
CELL DIFFERENTIATION;
CELL GROWTH;
CLINICAL TRIAL;
CUTANEOUS T CELL LYMPHOMA;
DRUG INDUSTRY;
DRUG POTENTIATION;
DRUG RECEPTOR BINDING;
DRUG RESEARCH;
ENERGY METABOLISM;
FOOD AND DRUG ADMINISTRATION;
GENETIC TRANSCRIPTION;
HUMAN;
LIVER DYSFUNCTION;
MEDICAL SOCIETY;
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
SYMPOSIUM;
UNITED STATES;
|
|
EID: 11444267327
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/96.24.1807 Document Type: Note |
|
Times cited : (12)
|
|
References (0)
|